Acura Pharmaceuticals received a $100,000 loan from Abuse Deterrent Pharma, LLC on each of September 18 and October 2, 2026. The loans were added to its secured promissory note, which had a principal balance of $11,294,279 and approximately $1,365,000 in accrued interest as of September 30, 2026; the note bears interest at 5.25%. Acura said the funding was used for day-to-day operations.
Overdue amounts bear interest at 7.5% per year from nonpayment until paid. Events of default include bankruptcy events, failure to pay principal or interest that continues for five days, and Acura generally not being able to pay its debts as they become due, being unable to do so, or admitting in writing its inability to do so. Acura said that without additional financing by mid-October 2026, it will be required to scale back operations, including furloughing or laying off employees, or terminate operations and/or seek bankruptcy protection; this could result in a complete loss of shareholder value. Acura also identified December 31, 2026 as the date by which it is required to pay off the note and accrued interest.
ACURA PHARMACEUTICALS, INC (ACUR) reports that its Quarterly Report on Form 10-Q for the period ended June 30, 2026 will not be filed on time due to liquidity constraints affecting its ability to meet day-to-day operating obligations. The company states it is working on funding solutions and is currently dependent on loans from Abuse Deterrent Pharma, LLC to fund operations, while acknowledging there is no assurance such loans will continue or be sufficient.
Acura discloses that it has not filed its Annual Reports on Form 10-K for the years ended December 31, 2022, 2023, 2024 and 2025, nor any Quarterly Reports on Form 10-Q for the fiscal years 2022 through 2025 and for the quarter ended March 31, 2026. It has halted its public accounting firm’s review of 2022 and 2023 quarterly results and audits of 2022 and 2023 annual results, and has not engaged an independent registered public accounting firm for 2024, 2025 or 2026. The company states that it cannot provide assurance it will be successful in filing these reports or securing funding solutions.
ACURA PHARMACEUTICALS, INC. (ACUR) reported that on August 14, 2026 it received a new $200,000 loan from Abuse Deterrent Pharma, LLC under an Amended, Consolidated and Restated Secured Promissory Note. Including this advance and prior loans, the Note’s principal balance is $11,094,279 with approximately $1,290,000 of accrued interest as of August 14, 2026, bearing interest at 5.25% and increasing to 7.5% on overdue amounts after any applicable grace period.
The loan proceeds were used to fund day-to-day operations, and Acura states there can be no assurance of obtaining additional financing. Without new funding by late‑September 2026, Acura indicates it would need to scale back operations, furlough or lay off employees, or potentially terminate operations and/or seek bankruptcy protection, which could result in a complete loss of shareholder value. The Note includes customary events of default, and Acura also references a requirement to obtain FDA acceptance of a New Drug Application for LTX‑03 and to repay the secured note and accrued interest by December 31, 2026, both of which it may seek to renegotiate.
Acura Pharmaceuticals, Inc. received a new $200,000 loan from Abuse Deterrent Pharma, LLC on July 17, 2026 under its existing secured promissory note, bringing total principal owed to $10,894,279 plus about $1,200,000 of accrued interest as of that date.
The note bears 5.25% annual interest, with 7.5% on overdue amounts and typical events of default. Management states the funding was used for day‑to‑day operations and warns that without additional financing by mid‑August 2026 it may have to scale back, furlough or lay off employees, terminate operations and/or seek bankruptcy protection, which it states could result in a complete loss of shareholder value. The company also cites obligations to obtain FDA acceptance of an NDA for LTX‑03 and to repay the note and interest by December 31, 2026, alongside extensive regulatory and development risks for its LIMITx and Impede technologies.
Acura Pharmaceuticals reports new financing and amended agreements with its main partner and creditor, Abuse Deterrent Pharma (AD Pharma). Between May 15 and June 24, 2026, AD Pharma advanced an additional $400,000 in loans, bringing the secured promissory note to $10,694,279 in principal with about $1,160,000 of accrued interest at a 5.25% rate.
The company warns it needs additional financing by late July 2026 to avoid scaling back or potentially terminating operations, which could wipe out shareholder value. Acura and AD Pharma also extended key dates to December 31, 2026: the FDA acceptance deadline for the LTX-03 New Drug Application, the note’s maturity, and the expiration of AD Pharma’s warrant. AD Pharma owns about 65% of Acura’s common stock, while an entity controlled by John Schutte owns an additional 13%, highlighting Acura’s dependence on this funding relationship.
Acura Pharmaceuticals notified the SEC that its Quarterly Report on Form 10-Q for the period ended March 31, 2026 will not be filed on time because of the company’s liquidity and its ability to meet day-to-day operating obligations.
The company discloses it is dependent on loans from Abuse Deterrent Pharma, LLC, has halted audit and review services for prior years, and has not filed Annual Reports for 2022 through 2025 or Quarterly Reports for fiscal years 2022 through 2025. The registrant states it cannot assure successful filing or continued receipt of loans.
Acura Pharmaceuticals, Inc. reports receiving four additional $100,000 loans from Abuse Deterrent Pharma, LLC between March 30 and May 5, 2026. These loans, together with earlier borrowings under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, bring the principal balance to $10,294,279, with approximately $1,090,000 of accrued interest as of May 5, 2026. The note bears interest at 5.25%, with overdue amounts accruing at 7.5%, and includes events of default such as bankruptcy and failure to pay amounts due.
The funding from AD Pharma is being used for day-to-day operations. Acura states that without additional financing by the end of May 2026, it may need to scale back operations, furlough or lay off employees, or terminate operations and possibly seek bankruptcy protection, which could result in a complete loss of shareholder value. AD Pharma owned approximately 65% of Acura’s outstanding common stock as of April 30, 2026, and holds a warrant for 10.0 million additional shares, while Mr. Schutte directly owned about 13% of the outstanding common stock.
Acura Pharmaceuticals, Inc. notified the SEC it cannot timely file its Annual Report on Form 10-K for the period ended December 31, 2025 due to liquidity constraints and dependence on loans from Abuse Deterrent Pharma, LLC. The company also states it has not filed Annual Reports for 2022–2024 or any Quarterly Reports for fiscal years 2022–2025. The notification states the registrant has halted its public accounting firm’s review and audit services for prior years pending funding and that no assurance can be given funding or filings will be completed.
Acura Pharmaceuticals reports new related-party financing and mounting liquidity pressure. On February 6, February 13 and March 9, 2026, the company received three loans of $100,000 each from Abuse Deterrent Pharma, LLC under an amended secured promissory note bearing 5.25% interest. Including prior advances, the note’s principal balance is $9,894,279 with about $1,040,000 of accrued interest as of February 28, 2026, and defaulted amounts accrue at 7.5%. The funding supports day-to-day operations, but management warns that without additional financing by the end of March 2026, it may have to scale back, furlough or lay off employees, or terminate operations and potentially seek bankruptcy protection, which could wipe out shareholder value. AD Pharma directly owns roughly 65% of the common stock and holds a warrant for 10 million shares, while its controlling member, Mr. Schutte, directly owns about 13%, highlighting concentrated, related-party control of both equity and debt.
Acura Pharmaceuticals, Inc. received three new $100,000 loans from Abuse Deterrent Pharma, LLC (AD Pharma) on December 31, 2025, January 2, 2026 and January 16, 2026 under its existing secured promissory note. These new advances, together with prior loans and $2,319,279 under the November 10, 2022 amended note, bring total principal to $9,594,279 with approximately $980,000 of accrued interest as of January 15, 2026, bearing interest at 5.25% and 7.5% on overdue amounts. The company states the funding will support day-to-day operations and warns that without additional financing by the end of January 2026 it may have to scale back or terminate operations, furlough or lay off employees, and potentially seek protection under bankruptcy laws, which could result in a complete loss of shareholder value. As of January 15, 2026, AD Pharma owns about 65% of the common stock and holds a warrant for 10.0 million shares, while Mr. Schutte directly owns about 13%.